Mon05202019

Robins Global News & Noticias



  • Shipping Advice
    Shipping Advice
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Featured Guest Post
    Featured Guest Post
  • Trump Pence News
    Trump Pence News
  • Weather Alerts
    Weather Alerts

RobinsPost News Network

+ Larger Font | + Smaller Font

Globe NewsWire News Distribution Service

Press Release: Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting


REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its research-use-only (RUO) LUNAR liquid biopsy.
For patients with advanced cancer, these include multiple investigations of the GuardantOMNI assay’s ability to identify patients who may benefit from treatment with immunotherapy. Additionally, researchers will present Guardant360 data to demonstrate the effectiveness of new targeted drugs, as well as the feasibility of serial ctDNA analysis to rapidly predict treatment response and long-term clinical benefit.For patients with early stage disease, the presentations include an analytical validation of Guardant’s LUNAR assay (Abstract 3057), as well as a pilot study exploring the LUNAR assay’s ability to identify early-stage colorectal cancer patients who may benefit from adjuvant therapy after undergoing an intervention with curative intent (Abstract 3602). This is a particularly challenging clinical setting for the detection of circulating tumor DNA in blood because patients who have undergone curative-intent interventions typically have little-to-no evidence of disease, and very low residual tumor DNA shedding in circulation.“Guardant is committed to expanding the benefits of precision oncology across the continuum of care,” said Guardant Health Chief Medical Officer Dr. Richard Lanman. “The new insights we and our research partners will bring to ASCO this year continue to demonstrate the many advantages of blood-based genomic testing over tissue-based genomic testing in support of a blood-first paradigm in early stage and late stage cancer.”Guardant’s data will be featured in the following presentations at ASCO this year:About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower ...


Posted: 2019-05-16 01:52:00

Get Full News Story On GlobeNewsWire Press Release Service


Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.


Print Friendly and PDF Share Embed


Related News Stories From The Web And More

Related Bing News

Press Release: Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting Nasdaq:GH

Wed, 15 May 2019 20:14:00 GMT

will present 27 abstracts at the ASCO Annual Meeting detailing new insights into precision oncology generated from its commercially available Guardant360 and GuardantOMNI assays, as well as its ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Wed, 15 May 2019 19:07:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Wed, 15 May 2019 07:52:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq:GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 ...

Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting

Tue, 14 May 2019 17:00:00 GMT

REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), along with researchers from leading academic institutions and pharmaceutical companies, will present 27 ...

Remarks by Commissioner Gottlieb to the American Society of Clinical Oncology (ASCO) Annual Meeting

Fri, 01 Jun 2018 17:00:00 GMT

I want to thank ASCO for the opportunity to speak here ... And I want to highlight some of the new initiatives we’re pursuing across the continuum of drug development – from clinical trial recruitment ...

Related Bing Web Search

Health IT Conferences

(Fri, 17 May 2019 01:44:00 GMT)

It is hard to keep track of all of the Health IT conferences. This information is scattered across a sponsoring organizations site, a few ‘top 10’ lists, advertisements for a conference, an article talking about an upcoming conference, etc. HealthItConferences.com gathers this information in a single location.

CME Meetings - audio-digest.org

(Fri, 17 May 2019 05:47:00 GMT)

About us. For over 65 years, Audio Digest has been a premier provider of quality audio continuing medical education. We provide content that is current and relevant to your practice in the most convenient way, allowing you to stay abreast of developments in your field and improve your standards of care for your patients.

American Society of Clinical Oncology (ASCO) | LinkedIn

(Fri, 17 May 2019 14:44:00 GMT)

About us. Founded in 1964, the American Society of Clinical Oncology (ASCO) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO ...

Press Room | Biotheranostics

(Fri, 17 May 2019 17:43:00 GMT)

November 28, 2018 Biotheranostics, Inc. announces recommendations for Breast Cancer Index in both the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and the American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update: Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer…

Site Map - Optum

(Thu, 16 May 2019 09:23:00 GMT)

Data and analytics; Pharmacy care services; Population health management; Health care delivery; Health care operations; Advisory services; Solutions for individuals and families

BCOP courses - Hematology/Oncology Pharmacy Association

(Fri, 17 May 2019 11:23:00 GMT)

HOPA supports pharmacy practitioners and seeks to promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer

Faculty Scholarly Activity : College of Nursing and Health ...

(Thu, 16 May 2019 12:43:00 GMT)

Antolchick, Jeanne, PhD, APRN, CRNA. Assistant Professor. Presentations. Apr 2018 - Moffitt Cancer Center, Anesthesia Department – An Introduction to Non-Opioid Anesthesia & Its Implications for Patient Care

PRIME® Continuing Medical Education | PRIME®

(Thu, 16 May 2019 21:47:00 GMT)

PRIME is an ACCME accredited provider of continuing medical education for Physicians, Physician Assistants, Pharmacists, Nurse Practitioners, Psychologists, Nurses and Case Managers

PRIME® Continuing Medical Education | PRIME®

(Fri, 17 May 2019 15:48:00 GMT)

PRIME is an ACCME accredited provider of continuing medical education for Physicians, Physician Assistants, Pharmacists, Nurse Practitioners, Psychologists, Nurses and Case Managers

Managing Upper Extremity Dysfunction in Breast Cancer ...

(Sat, 09 Jul 2016 23:59:00 GMT)

Tweet this quote. With an increased number of breast cancer survivors and patients with metastatic disease living longer, it is imperative for oncology care providers to manage issues of new and chronic upper extremity dysfunction as a result of the malignancy itself or its treatment.

Related News Story Videos From Youtube

Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting


Related Videos On: Dr. Monica Bertagnolli Invites You to the 2019 ASCO Annual Meeting


Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018


Related Videos On: Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018


Highlights of Breast Cancer Research from ASCO 2014


Related Videos On: Highlights of Breast Cancer Research from ASCO 2014


Key Insights: Lymphoma & Myeloma 2017 - Lymphoma


Related Videos On: Key Insights: Lymphoma & Myeloma 2017 - Lymphoma


New agents on the horizon in gastric cancer


Related Videos On: New agents on the horizon in gastric cancer






Blow Us A Whistle

Comments (Whistles) Designed By Disqus




Company Information

Official Content Providers











PRIVACY POLICY

We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
© 2008-2019 RobinsPost (The Bird's Eye View Company) All rights are reserved.
RobinsPost provides links to news sites based on their RSS feeds.
All trademarks, copyrights, videos, photos and logos are owned by news sources.
News stories, videos and live streams are from trusted sources:
Bing News, Google News, NewsApi.org and YouTube Search Results.
ROBINSPOST Is Proudly Made In America.
Where Quality, Safety and Service Comes First.